Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 33 entries
Sorted by: Best Match Show Resources per page
Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy.

Translational oncology

Timotheadou E, Kalogeras KT, Koliou GA, Wirtz RM, Zagouri F, Koutras A, Veltrup E, Christodoulou C, Pentheroudakis G, Tsiftsoglou A, Papakostas P, Aravantinos G, Venizelos V, Pectasides D, Kosmidis P, Karanikiotis C, Markopoulos C, Gogas H, Fountzilas G.
PMID: 28666187
Transl Oncol. 2017 Aug;10(4):589-598. doi: 10.1016/j.tranon.2017.05.006. Epub 2017 Jun 27.

BACKGROUND: Prevention of bone metastases is a major issue for breast cancer patients, as it would improve quality of life in a population where long survival is anticipated.PATIENTS AND METHODS: Early breast cancer patients, who had been treated with...

Cite
Timotheadou E, Kalogeras KT, Koliou GA, et al. Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. Transl Oncol. 2017;10(4):589-598doi: 10.1016/j.tranon.2017.05.006.
Timotheadou, E., Kalogeras, K. T., Koliou, G. A., Wirtz, R. M., Zagouri, F., Koutras, A., Veltrup, E., Christodoulou, C., Pentheroudakis, G., Tsiftsoglou, A., Papakostas, P., Aravantinos, G., Venizelos, V., Pectasides, D., Kosmidis, P., Karanikiotis, C., Markopoulos, C., Gogas, H., & Fountzilas, G. (2017). Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. Translational oncology, 10(4), 589-598. https://doi.org/10.1016/j.tranon.2017.05.006
Timotheadou, Eleni, et al. "Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy." Translational oncology vol. 10,4 (2017): 589-598. doi: https://doi.org/10.1016/j.tranon.2017.05.006
Timotheadou E, Kalogeras KT, Koliou GA, Wirtz RM, Zagouri F, Koutras A, Veltrup E, Christodoulou C, Pentheroudakis G, Tsiftsoglou A, Papakostas P, Aravantinos G, Venizelos V, Pectasides D, Kosmidis P, Karanikiotis C, Markopoulos C, Gogas H, Fountzilas G. Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. Transl Oncol. 2017 Aug;10(4):589-598. doi: 10.1016/j.tranon.2017.05.006. Epub 2017 Jun 27. PMID: 28666187; PMCID: PMC5491451.
Copy Download .nbib Format: NLM
Percutaneous management of lymphocoeles following pelvic lymphadenectomy for cervical carcinoma.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology

Daskalakis G, Mesogitis S, Antsaklis A, Papantoniou N, Papageorgiou I, Michalas S, Aravantinos D.
PMID: 15511820
J Obstet Gynaecol. 1997 Mar;17(2):192-4. doi: 10.1080/01443619750113852.

Eighteen patients with 26 pelvic lymphocoeles following radical hysterectomy underwent percutaneous therapeutic intervention with either needle aspiration, or catheter drainage. In eight patients a percutaneous needle aspiration under sonographic control was performed. Five out of eight patients were successfully...

Cite
Daskalakis G, Mesogitis S, Antsaklis A, et al. Percutaneous management of lymphocoeles following pelvic lymphadenectomy for cervical carcinoma. J Obstet Gynaecol. 1997;17(2):192-4doi: 10.1080/01443619750113852.
Daskalakis, G., Mesogitis, S., Antsaklis, A., Papantoniou, N., Papageorgiou, I., Michalas, S., & Aravantinos, D. (1997). Percutaneous management of lymphocoeles following pelvic lymphadenectomy for cervical carcinoma. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 17(2), 192-4. https://doi.org/10.1080/01443619750113852
Daskalakis, G, et al. "Percutaneous management of lymphocoeles following pelvic lymphadenectomy for cervical carcinoma." Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology vol. 17,2 (1997): 192-4. doi: https://doi.org/10.1080/01443619750113852
Daskalakis G, Mesogitis S, Antsaklis A, Papantoniou N, Papageorgiou I, Michalas S, Aravantinos D. Percutaneous management of lymphocoeles following pelvic lymphadenectomy for cervical carcinoma. J Obstet Gynaecol. 1997 Mar;17(2):192-4. doi: 10.1080/01443619750113852. PMID: 15511820.
Copy Download .nbib Format: NLM
MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.

Journal of oncology

Fountzilas G, Kalogera-Fountzila A, Lambaki S, Wirtz RM, Nikolaou A, Karayannopoulou G, Bobos M, Kotoula V, Murray S, Lambropoulos A, Aravantinos G, Markou K, Athanassiou E, Misailidou D, Kalogeras KT, Skarlos D.
PMID: 20066159
J Oncol. 2009;2009:305908. doi: 10.1155/2009/305908. Epub 2009 Dec 29.

Concomitant administration of radiotherapy with cisplatin or radiotherapy with cetuximab appear to be the treatment of choice for patients with locally advanced head and neck cancer. In the present retrospective analysis, we investigated the predictive role of several biomarkers...

Cite
Fountzilas G, Kalogera-Fountzila A, Lambaki S, et al. MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. J Oncol. 2009;2009:305908doi: 10.1155/2009/305908.
Fountzilas, G., Kalogera-Fountzila, A., Lambaki, S., Wirtz, R. M., Nikolaou, A., Karayannopoulou, G., Bobos, M., Kotoula, V., Murray, S., Lambropoulos, A., Aravantinos, G., Markou, K., Athanassiou, E., Misailidou, D., Kalogeras, K. T., & Skarlos, D. (2009). MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. Journal of oncology, 2009305908. https://doi.org/10.1155/2009/305908
Fountzilas, George, et al. "MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer." Journal of oncology vol. 2009 (2009): 305908. doi: https://doi.org/10.1155/2009/305908
Fountzilas G, Kalogera-Fountzila A, Lambaki S, Wirtz RM, Nikolaou A, Karayannopoulou G, Bobos M, Kotoula V, Murray S, Lambropoulos A, Aravantinos G, Markou K, Athanassiou E, Misailidou D, Kalogeras KT, Skarlos D. MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. J Oncol. 2009;2009:305908. doi: 10.1155/2009/305908. Epub 2009 Dec 29. PMID: 20066159; PMCID: PMC2801452.
Copy Download .nbib Format: NLM
A giant inguinoscrotal bladder hernia as a cause of chronic renal failure: A rare case.

International journal of surgery case reports

Karatzas A, Christodoulidis G, Spyridakis M, Stavaras C, Aravantinos E, Melekos M.
PMID: 23416505
Int J Surg Case Rep. 2013;4(3):345-7. doi: 10.1016/j.ijscr.2012.12.011. Epub 2013 Jan 26.

INTRODUCTION: Giant inguinoscrotal bladder hernias are very rare and require surgical intervention. They usually do not cause any specific symptoms and thus, they are often misdiagnosed. If left untreated though, they might lead to severe medical conditions, such as...

Cite
Karatzas A, Christodoulidis G, Spyridakis M, et al. A giant inguinoscrotal bladder hernia as a cause of chronic renal failure: A rare case. Int J Surg Case Rep. 2013;4(3):345-7doi: 10.1016/j.ijscr.2012.12.011.
Karatzas, A., Christodoulidis, G., Spyridakis, M., Stavaras, C., Aravantinos, E., & Melekos, M. (2013). A giant inguinoscrotal bladder hernia as a cause of chronic renal failure: A rare case. International journal of surgery case reports, 4(3), 345-7. https://doi.org/10.1016/j.ijscr.2012.12.011
Karatzas, Anastasios, et al. "A giant inguinoscrotal bladder hernia as a cause of chronic renal failure: A rare case." International journal of surgery case reports vol. 4,3 (2013): 345-7. doi: https://doi.org/10.1016/j.ijscr.2012.12.011
Karatzas A, Christodoulidis G, Spyridakis M, Stavaras C, Aravantinos E, Melekos M. A giant inguinoscrotal bladder hernia as a cause of chronic renal failure: A rare case. Int J Surg Case Rep. 2013;4(3):345-7. doi: 10.1016/j.ijscr.2012.12.011. Epub 2013 Jan 26. PMID: 23416505; PMCID: PMC3604660.
Copy Download .nbib Format: NLM
Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative.

Oncotarget

Fountzilas E, Kotoula V, Koliou GA, Giannoulatou E, Gogas H, Papadimitriou C, Tikas I, Zhang J, Papadopoulou K, Zagouri F, Christodoulou C, Koutras A, Makatsoris T, Chrisafi S, Linardou H, Varthalitis I, Papatsibas G, Razis E, Papakostas P, Samantas E, Aravantinos G, Bafaloukos D, Kosmidis P, Koumarianou A, Psyrri A, Pentheroudakis G, Pectasides D, Futreal A, Fountzilas G, Tsimberidou AM.
PMID: 32002119
Oncotarget. 2020 Jan 07;11(1):1-14. doi: 10.18632/oncotarget.27338. eCollection 2020 Jan 07.

No abstract available.

Cite
Fountzilas E, Kotoula V, Koliou GA, et al. Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. Oncotarget. 2020;11(1):1-14doi: 10.18632/oncotarget.27338.
Fountzilas, E., Kotoula, V., Koliou, G. A., Giannoulatou, E., Gogas, H., Papadimitriou, C., Tikas, I., Zhang, J., Papadopoulou, K., Zagouri, F., Christodoulou, C., Koutras, A., Makatsoris, T., Chrisafi, S., Linardou, H., Varthalitis, I., Papatsibas, G., Razis, E., Papakostas, P., Samantas, E., Aravantinos, G., Bafaloukos, D., Kosmidis, P., Koumarianou, A., Psyrri, A., Pentheroudakis, G., Pectasides, D., Futreal, A., Fountzilas, G., & Tsimberidou, A. M. (2020). Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. Oncotarget, 11(1), 1-14. https://doi.org/10.18632/oncotarget.27338
Fountzilas, Elena, et al. "Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative." Oncotarget vol. 11,1 (2020): 1-14. doi: https://doi.org/10.18632/oncotarget.27338
Fountzilas E, Kotoula V, Koliou GA, Giannoulatou E, Gogas H, Papadimitriou C, Tikas I, Zhang J, Papadopoulou K, Zagouri F, Christodoulou C, Koutras A, Makatsoris T, Chrisafi S, Linardou H, Varthalitis I, Papatsibas G, Razis E, Papakostas P, Samantas E, Aravantinos G, Bafaloukos D, Kosmidis P, Koumarianou A, Psyrri A, Pentheroudakis G, Pectasides D, Futreal A, Fountzilas G, Tsimberidou AM. Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. Oncotarget. 2020 Jan 07;11(1):1-14. doi: 10.18632/oncotarget.27338. eCollection 2020 Jan 07. PMID: 32002119; PMCID: PMC6967777.
Copy Download .nbib Format: NLM
Genetic polymorphisms of interleukin 1β gene and sporadic pancreatic neuroendocrine tumors susceptibility.

World journal of gastrointestinal oncology

Karakaxas D, Sioziou A, Aravantinos G, Coker A, Papanikolaou IS, Liakakos T, Dervenis C, Gazouli M.
PMID: 27326321
World J Gastrointest Oncol. 2016 Jun 15;8(6):520-5. doi: 10.4251/wjgo.v8.i6.520.

AIM: To evaluate the association between the interleukin 1β (IL-1β) polymorphisms and the pancreatic neuroendocrine tumor (pNET) development.METHODS: A case-control study was conducted analyzing IL-1β polymorphisms using germline DNA collected in a population-based case-control study of pancreatic cancer (51...

Cite
Karakaxas D, Sioziou A, Aravantinos G, et al. Genetic polymorphisms of interleukin 1β gene and sporadic pancreatic neuroendocrine tumors susceptibility. World J Gastrointest Oncol. 2016;8(6):520-5doi: 10.4251/wjgo.v8.i6.520.
Karakaxas, D., Sioziou, A., Aravantinos, G., Coker, A., Papanikolaou, I. S., Liakakos, T., Dervenis, C., & Gazouli, M. (2016). Genetic polymorphisms of interleukin 1β gene and sporadic pancreatic neuroendocrine tumors susceptibility. World journal of gastrointestinal oncology, 8(6), 520-5. https://doi.org/10.4251/wjgo.v8.i6.520
Karakaxas, Dimitrios, et al. "Genetic polymorphisms of interleukin 1β gene and sporadic pancreatic neuroendocrine tumors susceptibility." World journal of gastrointestinal oncology vol. 8,6 (2016): 520-5. doi: https://doi.org/10.4251/wjgo.v8.i6.520
Karakaxas D, Sioziou A, Aravantinos G, Coker A, Papanikolaou IS, Liakakos T, Dervenis C, Gazouli M. Genetic polymorphisms of interleukin 1β gene and sporadic pancreatic neuroendocrine tumors susceptibility. World J Gastrointest Oncol. 2016 Jun 15;8(6):520-5. doi: 10.4251/wjgo.v8.i6.520. PMID: 27326321; PMCID: PMC4909453.
Copy Download .nbib Format: NLM
Real-World Data on Treatment Management and Outcomes of Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer in Greece (The EpOCa Study).

Current oncology (Toronto, Ont.)

Liontos M, Timotheadou E, Papadopoulos EI, Zafeiriou Z, Lampropoulou DI, Aravantinos G, Mavroudis D, Christodoulou C, Nikolaidi A, Somarakis A, Papadimitriou C, Papandreou C, Bamias A.
PMID: 34940079
Curr Oncol. 2021 Dec 10;28(6):5266-5277. doi: 10.3390/curroncol28060440.

New treatment modalities have been recently introduced in the management of ovarian cancer (OC). Herein, we sought to investigate their implementation in routine clinical practice and examine the real-world management of OC in Greece. EpOCa was a non-interventional, multicenter,...

Cite
Liontos M, Timotheadou E, Papadopoulos EI, et al. Real-World Data on Treatment Management and Outcomes of Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer in Greece (The EpOCa Study). Curr Oncol. 2021;28(6):5266-5277doi: 10.3390/curroncol28060440.
Liontos, M., Timotheadou, E., Papadopoulos, E. I., Zafeiriou, Z., Lampropoulou, D. I., Aravantinos, G., Mavroudis, D., Christodoulou, C., Nikolaidi, A., Somarakis, A., Papadimitriou, C., Papandreou, C., & Bamias, A. (2021). Real-World Data on Treatment Management and Outcomes of Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer in Greece (The EpOCa Study). Current oncology (Toronto, Ont.), 28(6), 5266-5277. https://doi.org/10.3390/curroncol28060440
Liontos, Michalis, et al. "Real-World Data on Treatment Management and Outcomes of Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer in Greece (The EpOCa Study)." Current oncology (Toronto, Ont.) vol. 28,6 (2021): 5266-5277. doi: https://doi.org/10.3390/curroncol28060440
Liontos M, Timotheadou E, Papadopoulos EI, Zafeiriou Z, Lampropoulou DI, Aravantinos G, Mavroudis D, Christodoulou C, Nikolaidi A, Somarakis A, Papadimitriou C, Papandreou C, Bamias A. Real-World Data on Treatment Management and Outcomes of Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer in Greece (The EpOCa Study). Curr Oncol. 2021 Dec 10;28(6):5266-5277. doi: 10.3390/curroncol28060440. PMID: 34940079.
Copy Download .nbib Format: NLM
Trends of Antithrombotic Treatment in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights from the GReek-AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.

Cardiovascular drugs and therapy

Benetou DR, Varlamos C, Ktenas D, Tsiafoutis I, Koutouzis M, Bampali T, Mantis C, Zarifis J, Skalidis E, Aravantinos D, Varvarousis D, Lianos I, Kanakakis J, Pisimisis E, Ziakas A, Davlouros P, Alexopoulos D.
PMID: 33034806
Cardiovasc Drugs Ther. 2021 Feb;35(1):11-20. doi: 10.1007/s10557-020-07090-x. Epub 2020 Oct 09.

PURPOSE: Patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) are a high-risk subset of patients, whose optimal antithrombotic treatment strategy, involving a combination of anticoagulant and antiplatelet agents, has not been well defined. Our study aims to...

Cite
Benetou DR, Varlamos C, Ktenas D, et al. Trends of Antithrombotic Treatment in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights from the GReek-AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry. Cardiovasc Drugs Ther. 2020;35(1):11-20doi: 10.1007/s10557-020-07090-x.
Benetou, D. R., Varlamos, C., Ktenas, D., Tsiafoutis, I., Koutouzis, M., Bampali, T., Mantis, C., Zarifis, J., Skalidis, E., Aravantinos, D., Varvarousis, D., Lianos, I., Kanakakis, J., Pisimisis, E., Ziakas, A., Davlouros, P., Alexopoulos, D. (2021). Trends of Antithrombotic Treatment in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights from the GReek-AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry. Cardiovascular drugs and therapy, 35(1), 11-20. https://doi.org/10.1007/s10557-020-07090-x
Benetou, Despoina-Rafailia, et al. "Trends of Antithrombotic Treatment in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights from the GReek-AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry." Cardiovascular drugs and therapy vol. 35,1 (2021): 11-20. doi: https://doi.org/10.1007/s10557-020-07090-x
Benetou DR, Varlamos C, Ktenas D, Tsiafoutis I, Koutouzis M, Bampali T, Mantis C, Zarifis J, Skalidis E, Aravantinos D, Varvarousis D, Lianos I, Kanakakis J, Pisimisis E, Ziakas A, Davlouros P, Alexopoulos D. Trends of Antithrombotic Treatment in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights from the GReek-AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry. Cardiovasc Drugs Ther. 2021 Feb;35(1):11-20. doi: 10.1007/s10557-020-07090-x. Epub 2020 Oct 09. PMID: 33034806.
Copy Download .nbib Format: NLM
Assessment of the antiosteoporotic treatment initiation: A retrospective observational study in Greece.

Journal of frailty, sarcopenia and falls

Rizou S, Aravantinos L, Paganas A, Ballas M, Lyritis GP.
PMID: 32300684
J Frailty Sarcopenia Falls. 2017 Dec 01;2(4):78-82. doi: 10.22540/JFSF-02-078. eCollection 2017 Dec.

OBJECTIVE: A study to retrospectively assess the decision to implement treatment for osteoporosis based on Greek version of FRAX tool.METHODS: The study population was 1000 postmenopausal women aged 45 or above, excluding those with medical conditions demanding specific osteoporosis...

Cite
Rizou S, Aravantinos L, Paganas A, et al. Assessment of the antiosteoporotic treatment initiation: A retrospective observational study in Greece. J Frailty Sarcopenia Falls. 2017;2(4):78-82doi: 10.22540/JFSF-02-078.
Rizou, S., Aravantinos, L., Paganas, A., Ballas, M., & Lyritis, G. P. (2017). Assessment of the antiosteoporotic treatment initiation: A retrospective observational study in Greece. Journal of frailty, sarcopenia and falls, 2(4), 78-82. https://doi.org/10.22540/JFSF-02-078
Rizou, Stavroula, et al. "Assessment of the antiosteoporotic treatment initiation: A retrospective observational study in Greece." Journal of frailty, sarcopenia and falls vol. 2,4 (2017): 78-82. doi: https://doi.org/10.22540/JFSF-02-078
Rizou S, Aravantinos L, Paganas A, Ballas M, Lyritis GP. Assessment of the antiosteoporotic treatment initiation: A retrospective observational study in Greece. J Frailty Sarcopenia Falls. 2017 Dec 01;2(4):78-82. doi: 10.22540/JFSF-02-078. eCollection 2017 Dec. PMID: 32300684; PMCID: PMC7155366.
Copy Download .nbib Format: NLM
Experimental Oral Herpes Simplex Virus-1 (HSV-1) Co-infection in Simian Immunodeficiency Virus (SIV)-Infected Rhesus Macaques.

Frontiers in microbiology

Aravantinou M, Mizenina O, Calenda G, Kenney J, Frank I, Lifson JD, Szpara M, Jing L, Koelle DM, Teleshova N, Grasperge B, Blanchard J, Gettie A, Martinelli E, Derby N.
PMID: 29259582
Front Microbiol. 2017 Dec 05;8:2342. doi: 10.3389/fmicb.2017.02342. eCollection 2017.

Herpes simplex virus 1 and 2 (HSV-1/2) similarly initiate infection in mucosal epithelia and establish lifelong neuronal latency. Anogenital HSV-2 infection augments the risk for sexual human immunodeficiency virus (HIV) transmission and is associated with higher HIV viral loads....

Cite
Aravantinou M, Mizenina O, Calenda G, et al. Experimental Oral Herpes Simplex Virus-1 (HSV-1) Co-infection in Simian Immunodeficiency Virus (SIV)-Infected Rhesus Macaques. Front Microbiol. 2017;8:2342doi: 10.3389/fmicb.2017.02342.
Aravantinou, M., Mizenina, O., Calenda, G., Kenney, J., Frank, I., Lifson, J. D., Szpara, M., Jing, L., Koelle, D. M., Teleshova, N., Grasperge, B., Blanchard, J., Gettie, A., Martinelli, E., & Derby, N. (2017). Experimental Oral Herpes Simplex Virus-1 (HSV-1) Co-infection in Simian Immunodeficiency Virus (SIV)-Infected Rhesus Macaques. Frontiers in microbiology, 82342. https://doi.org/10.3389/fmicb.2017.02342
Aravantinou, Meropi, et al. "Experimental Oral Herpes Simplex Virus-1 (HSV-1) Co-infection in Simian Immunodeficiency Virus (SIV)-Infected Rhesus Macaques." Frontiers in microbiology vol. 8 (2017): 2342. doi: https://doi.org/10.3389/fmicb.2017.02342
Aravantinou M, Mizenina O, Calenda G, Kenney J, Frank I, Lifson JD, Szpara M, Jing L, Koelle DM, Teleshova N, Grasperge B, Blanchard J, Gettie A, Martinelli E, Derby N. Experimental Oral Herpes Simplex Virus-1 (HSV-1) Co-infection in Simian Immunodeficiency Virus (SIV)-Infected Rhesus Macaques. Front Microbiol. 2017 Dec 05;8:2342. doi: 10.3389/fmicb.2017.02342. eCollection 2017. PMID: 29259582; PMCID: PMC5723348.
Copy Download .nbib Format: NLM
Recombinant human erythropoietin for platinum-based chemotherapy-induced anaemia: A single-centre randomised study.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Aravantinos G, Linardou H, Makridaki D, Laiou E, Zafiropoulos A, Janninis J, Sofos G, Gikas D, Samantas E, Markantoni-Kyroudi S.
PMID: 17472238
J BUON. 2003 Apr-Jun;8(2):127-32.

PURPOSE: Recombinant human erythropoietin (rHuEPO) represents an attractive alternative to red blood cell (RBC) transfusions for the treatment of chemotherapy-induced anaemia. This prospective, controlled study evaluated the safety and efficacy of rHuEPO in reducing RBC transfusion requirements in patients...

Cite
Aravantinos G, Linardou H, Makridaki D, et al. Recombinant human erythropoietin for platinum-based chemotherapy-induced anaemia: A single-centre randomised study. J BUON. 2003;8(2):127-32
Aravantinos, G., Linardou, H., Makridaki, D., Laiou, E., Zafiropoulos, A., Janninis, J., Sofos, G., Gikas, D., Samantas, E., & Markantoni-Kyroudi, S. (2003). Recombinant human erythropoietin for platinum-based chemotherapy-induced anaemia: A single-centre randomised study. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 8(2), 127-32.
Aravantinos, G, et al. "Recombinant human erythropoietin for platinum-based chemotherapy-induced anaemia: A single-centre randomised study." Journal of B.U.ON. : official journal of the Balkan Union of Oncology vol. 8,2 (2003): 127-32.
Aravantinos G, Linardou H, Makridaki D, Laiou E, Zafiropoulos A, Janninis J, Sofos G, Gikas D, Samantas E, Markantoni-Kyroudi S. Recombinant human erythropoietin for platinum-based chemotherapy-induced anaemia: A single-centre randomised study. J BUON. 2003 Apr-Jun;8(2):127-32. PMID: 17472238.
Copy Download .nbib Format: NLM
Determination of .

Oncology letters

Papadopoulou E, Tsoulos N, Tsirigoti A, Apessos A, Agiannitopoulos K, Metaxa-Mariatou V, Zarogoulidis K, Zarogoulidis P, Kasarakis D, Kakolyris S, Dahabreh J, Vlastos F, Zoublios C, Rapti A, Papageorgiou NG, Veldekis D, Gaga M, Aravantinos G, Karavasilis V, Karagiannidis N, Nasioulas G.
PMID: 26622815
Oncol Lett. 2015 Oct;10(4):2176-2184. doi: 10.3892/ol.2015.3600. Epub 2015 Aug 12.

It has been reported that certain patients with non-small-cell lung cancer (NSCLC) that harbor activating somatic mutations within the tyrosine kinase domain of the

Cite
Papadopoulou E, Tsoulos N, Tsirigoti A, et al. Determination of . Oncol Lett. 2015;10(4):2176-2184doi: 10.3892/ol.2015.3600.
Papadopoulou, E., Tsoulos, N., Tsirigoti, A., Apessos, A., Agiannitopoulos, K., Metaxa-Mariatou, V., Zarogoulidis, K., Zarogoulidis, P., Kasarakis, D., Kakolyris, S., Dahabreh, J., Vlastos, F., Zoublios, C., Rapti, A., Papageorgiou, N. G., Veldekis, D., Gaga, M., Aravantinos, G., Karavasilis, V., Karagiannidis, N., & Nasioulas, G. (2015). Determination of . Oncology letters, 10(4), 2176-2184. https://doi.org/10.3892/ol.2015.3600
Papadopoulou, Eirini, et al. "Determination of ." Oncology letters vol. 10,4 (2015): 2176-2184. doi: https://doi.org/10.3892/ol.2015.3600
Papadopoulou E, Tsoulos N, Tsirigoti A, Apessos A, Agiannitopoulos K, Metaxa-Mariatou V, Zarogoulidis K, Zarogoulidis P, Kasarakis D, Kakolyris S, Dahabreh J, Vlastos F, Zoublios C, Rapti A, Papageorgiou NG, Veldekis D, Gaga M, Aravantinos G, Karavasilis V, Karagiannidis N, Nasioulas G. Determination of . Oncol Lett. 2015 Oct;10(4):2176-2184. doi: 10.3892/ol.2015.3600. Epub 2015 Aug 12. PMID: 26622815; PMCID: PMC4579824.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 33 entries